Answer
Panitumumab (Vectibix) may reach the developing foetus and potentially cause foetal harm or pregnancy loss; adequate pregnancy data are lacking, animal studies showed reproductive toxicity, and the potential human risk is unknown.
Sources for this answer
- Vectibix 20 mg/mL concentrate for solution for infusionAmgen Ltd · emc · SmPC §4.6 Fertility, pregnancy and lactation · Version 27Document updated
Sources checked